Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “T(11;14)”

20 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 20 results

Early research (Phase 1)Active Not RecruitingNCT05391750
What this trial is testing

Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma

Who this might be right for
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
Emory University 7
Testing effectiveness (Phase 2)Active Not RecruitingNCT05451771
What this trial is testing

Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

Who this might be right for
AL Amyloidosis
Columbia University 53
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07687004
What this trial is testing

Sonrotoclax and BCMA Bispecific Antibody in Newly Diagnosed Systemic AL Amyloidosis Based on t(11;14) Genetic Stratification

Who this might be right for
Multiple Myeloma (MM)
Institute of Hematology & Blood Diseases Hospital, China 50
Testing effectiveness (Phase 2)WithdrawnNCT03701321
What this trial is testing

Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Active Not RecruitingNCT03872180
What this trial is testing

Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma

Who this might be right for
CCND1 PositiveMantle Cell Lymphomat(11;14) Positive
Emory University 23
Testing effectiveness (Phase 2)Study completedNCT05199337
What this trial is testing

Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis

Who this might be right for
AmyloidosisAL Amyloidosis
K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. 18
Testing effectiveness (Phase 2)WithdrawnNCT03785184
What this trial is testing

Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy

Who this might be right for
Multiple Myeloma
AbbVie
Large-scale testing (Phase 3)Active Not RecruitingNCT03539744
What this trial is testing

A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

Who this might be right for
Multiple Myeloma
AbbVie 265
Testing effectiveness (Phase 2)Looking for participantsNCT07335887
What this trial is testing

Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis

Who this might be right for
AL Amyloidosis (AL)t(11;14) Positive
Peking University People's Hospital 39
Testing effectiveness (Phase 2)Looking for participantsNCT04973605
What this trial is testing

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

Who this might be right for
Relapsed/Refractory Multiple Myeloma
BeOne Medicines 246
Testing effectiveness (Phase 2)Looking for participantsNCT05853965
What this trial is testing

Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple Myeloma

Who this might be right for
Multiple MyelomaMultiple Myeloma in Relapse
Universitätsklinikum Hamburg-Eppendorf 45
Post-approval studies (Phase 4)Not Yet RecruitingNCT07709884
What this trial is testing

A Single-center, Prospective, Single-arm Clinical Study Exploring the Treatment of Newly Diagnosed Multiple Myeloma Patients With t(11;14) Suitable for Transplantation Using the SonKRd Regimen

Who this might be right for
Newly Diagnosed Multiple MyelomaT(11;14)Sotoclax+1 more
The First Affiliated Hospital of Soochow University 20
Not applicableLooking for participantsNCT06192979
What this trial is testing

Optimize First-line Treatment for AL Amyloidosis With t (11; 14)

Who this might be right for
Amyloidosis; SystemicAL Amyloidosis
Jin Lu, MD 41
Not applicableStudy completedNCT04721002
What this trial is testing

Study to Evaluate t(11;14) Status and BCL2 Expression in Adult Participants With Multiple Myeloma (MM)

Who this might be right for
Multiple Myeloma (MM)
AbbVie 514
Testing effectiveness (Phase 2)WithdrawnNCT03856112
What this trial is testing

Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple Myeloma

Who this might be right for
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myelomat(11;14) Negative
National Cancer Institute (NCI)
Early research (Phase 1)Active Not RecruitingNCT06042725
What this trial is testing

MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma

Who this might be right for
Multiple Myeloma
Mayo Clinic 16
Testing effectiveness (Phase 2)Looking for participantsNCT05530421
What this trial is testing

Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma

Who this might be right for
Relapsed and Refractory Multiple Myeloma
University of Miami 33
Testing effectiveness (Phase 2)Active Not RecruitingNCT03946878
What this trial is testing

Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

Who this might be right for
Blastoid Variant Mantle Cell LymphomaCCND1 Protein OverexpressionCD20 Positive+6 more
M.D. Anderson Cancer Center 32
Testing effectiveness (Phase 2)Looking for participantsNCT06115135
What this trial is testing

Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma in RelapseMultiple Myeloma, Refractory
Oncotherapeutics 39
Early research (Phase 1)Study completedNCT03399539
What this trial is testing

Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients with Relapsed Multiple Myeloma

Who this might be right for
Recurrent Plasma Cell MyelomaT(11;14)
Mayo Clinic 8
Next Page